Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.49 |
| ▸ | ACACB | O00763 | 9/20 | 0.44 |
| ▸ | ACACA | Q13085 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.40 |
| ▸ | PLK1 | P53350 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4065254 | 0.85 | ELANE (0.55) | ELANEACACBACACALMNAALDH1A1 | |
| SCHEMBL4057131 | 0.84 | ELANE (0.49) | ELANEACACBACACAALDH1A1KMT2A | |
| SCHEMBL4064862 | 0.82 | ACACB (0.60) | ELANEACACBL3MBTL1 | |
| SCHEMBL4062305 | 0.82 | ACACB (0.49) | ACACBACACALMNAL3MBTL1PLK1 | |
| SCHEMBL4062391 | 0.82 | ELANE (0.55) | ELANELMNAALDH1A1L3MBTL1CYP1A2 | |
| SCHEMBL4061895 | 0.81 | ELANE (0.59) | ELANEACACBLMNAL3MBTL1PLK1 | |
| SCHEMBL4058555 | 0.81 | ELANE (0.59) | ELANEACACBLMNAL3MBTL1PLK1 | |
| SCHEMBL13845217 | 0.81 | ELANE (0.51) | ELANEACACBLMNAALDH1A1L3MBTL1 | |
| SCHEMBL4058207 | 0.81 | ELANE (0.54) | ELANELMNAALDH1A1CYP1A2MAPK1 | |
| SCHEMBL9176375 | 0.81 | ELANE (0.54) | ELANEACACBACACAFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7534547-B2 | Optically active compound and photosensitive resin composition | OSAKA GAS COMPANY LIMITED (JP) | 2009-05-19 | — | — | US | disclosed |
| EP-1375463-A1 | OPTICALLY ACTIVE COMPOUND AND PHOTOSENSITIVE RESIN COMPOSITION | Kansai Research Institute, Inc. (JP) | 2004-01-02 | — | — | EP | disclosed |
| US-20030211421-A1 | Optically active compound and photosensitive resin composition | KRI, INC. (JP) | 2003-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030211421-A1 | Optically active compound and photosensitive resin composition | ARCN1, RAD51, PAM | ELANE 422/4885ACACB 4685/4885ACACA 4235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.